William Jia, PhD
Dr. Jia graduated from Fudan University in 1982, majoring in Neurobiology. After achieving his master's degree in Psychology (1987) from Dalhousie University in Canada, he pursued his PhD at the University of British Columbia (UBC) and obtained his PhD in 1991. Dr. Jia is currently a principle investigator at the Brain Research Center of UBC, as the head of the oncolytic virus laboratory with title of associate professor of neurosurgery (tenured). Dr. Jia is one of the international pioneers in the use of recombinant oncolytic viruses to treat malignant tumors. In 1994, his research was published in the top oncology journal (JOURNAL OF NATIONAL CANCER INSTITUTE) with editorial comments.
Dr. Jia carried out a detailed study regarding the safety of oncolytic Herpes Simplex Virus and his research results were widely cited, including the gene therapy hearing of the US Congress.
In recent years, Dr. Jia and his research team proposed the concept of dual regulation of transcription and translation of oncolytic viruses. His team successfully developed a Herpes Simplex Virus enhanced in both safety and tumor killing activity. This concept is one of the most cutting-edge developments in the field.
Chris Huang, MBA, CFA
Mr. Huang graduated from Shanghai Fudan University with his undergraduate and graduate degrees, followed by financial training for CFA accreditation. Mr. Huang has now been a CFA (Chartered Financial Analyst) charter holder for numerous years.
As a senior entrepreneur and investment manager, Mr. Huang has been involved in the formation and management of a number of large pharmaceutical and chemical companies (including one listed on the Shenzhen Stock Exchange). Mr. Huang has extensive experience in business management and has served as the CEO of a public company for many years. He is both familiar with China's capital markets, and has an international vision. Serving as a senior consultant for the CEO of a venture capital company, Jiangxi Lattice Power, and as vice president of Hong-Cheng capital, Mr. Huang exemplifies his considerable experience in venture capital and corporate financing.
Dr. Chouljenko completed his PhD at Louisiana State University in 2014 and has over eight years of experience working with the Herpes Simplex Virus, with a number of important publications in peer-reviewed journals elucidating the details of viral replication and egress from infected host cells. Dr. Chouljenko has an extensive background in molecular virology and genetic engineering with a focus on recombinant virus construction, as well as expertise in the analysis of protein-protein interactions. Dr. Chouljenko is currently leading the development of novel therapeutic viral frameworks at Virogin.
Dr. Lee obtained her doctorate degree from the University of British Columbia in 2010. Dr. Lee specializes in tumor biology, cell immune biology, molecular biology and has many years of experience in both academic research and industrial environments. She is an expert in autoimmune diseases and anti-cancer drug development. Dr. Lee manages the experimental design and the verification of the immunological effects of the oncolytic viruses of Virogin.
Dr. Ding achieved her PhD at the China Agricultural University in 2009, majoring in Preventive Veterinary Medicine. Dr. Ding is specialized in molecular virology, and during her postdoctoral training at the University of British Columbia, Dr. Ding has been mainly focused on the antitumor activity of oncolytic viruses (HSV, VSV) in prostate cancer animal models. With many years of experience in tumor models and oncolytic viruses, Dr. Ding is responsible for in vivo verification of the antitumor activity of oncolytic viruses.